Johnson & Johnson Reports Final Results Of Exchange Offer And Finalizes Separation Of Kenvue
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has finalized the separation of Kenvue, retaining approximately 9.5% of the outstanding shares of Kenvue common stock. Johnson & Johnson will provide updated financials and 2023 guidance reflecting operations as a two-sector company focused on Pharmaceutical and MedTech innovation.
August 23, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson has finalized its separation from Kenvue, retaining 9.5% of Kenvue's shares. This could potentially impact JNJ's stock price.
The separation from Kenvue and the retention of 9.5% of its shares could potentially impact Johnson & Johnson's stock price. However, the exact impact will depend on the updated financials and 2023 guidance that the company will provide.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson has finalized its separation from Kenvue, retaining 9.5% of Kenvue's shares. This could potentially impact KVUE's stock price.
The separation from Johnson & Johnson and the fact that JNJ retains 9.5% of Kenvue's shares could potentially impact Kenvue's stock price. However, the exact impact will depend on the market's reaction to this news.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100